**Name of journal: World Journal of Transplantation**

**ESPS Manuscript No: 7936**

**Columns: Review**

ABO incompatible renal transplants: Good or bad?

Muramatsu M *et al*. ABO incompatible renal transplantation

Masaki Muramatsu, Hector Daniel Gonzalez, Roberto Cacciola, Atsushi Aikawa, Magdi M Yaqoob, Carmelo Puliatti

**Masaki Muramatsu,** **Magdi M Yaqoob,** Department of Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, United Kingdom

**Masaki Muramatsu,** **Atsushi Aikawa,** Department of Nephrology, Toho University Faculty of Medicine, Tokyo, 143-8541, Japan

**Hector Daniel Gonzalez, Roberto Cacciola, Magdi M Yaqoob, Carmelo Puliatti,** Transplant Unit, the Royal London Hospital, London, E1 1BB, United Kingdom

**Author contributions:** Muramatsu M, Cacciola R, Aikawa A, Yaqoob MM and Puliatti C contributed to conception and design, acquisition of data, or analysis and interpretation of data; Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM and Puliatti C contributed to drafting the article or revising it critically for important intellectual content; Muramatsu M, Yaqoob MM and Puliatti C contributed to final approval of the version to be published.

**Correspondence to: Carmelo Puliatti, MD,** Transplant Unit, The Royal London Hospital, Whitechapel Road, London, E1 1BB, United Kingdom. [Carmelo.Puliatti@bartshealth.nhs.uk](mailto:Carmelo.Puliatti@bartshealth.nhs.uk)

**Telephone:** +44-20-35942673 **Fax:** +44-20-35943248

**Received:** December 7, 2013 **Revised:** February 12, 2014

**Accepted: February 18, 2014**

**Published online:**

**Abstract**

ABO incompatible kidney transplantation (ABOi-KT) was previously considered to be an absolute contraindication for patients with end-stage kidney disease (ESKD) due to hyperacute rejection related to blood type barrier. Since the first successful series of ABOi-KT was reported, ABOi-KT is performed increasingly all over the world. ABOi-KT has led to an expanded donor pool and reduced the number of patients with ESKD awaiting deceased kidney transplantation (KT). Intensified immunosuppression and immunological understanding has helped to shape current desensitization protocols. Consequently, in recent years, ABOi-KT outcome is comparable to ABO compatible KT (ABOc-KT). However, still many questions remain unanswered. In ABOi-KT, there is an additional residual immunological risk that may lead to allograft damage, despite using current diverse but usually intensified immunosuppressive protocols at the expense of increasing risk of infection and possibly malignancy. Notably, in ABOi-KT, desensitization and antibody reduction therapies have increased the cost of KT. Reassuringly; there has been an evolution in ABOi-KT leading to a simplification of protocols over the last decade. This review provides an overview of the history, outcome, protocol, advantages and disadvantages in ABOi-KT, and focuses on whether ABOi-KT should be recommended as a therapeutic option of KT in the future.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key word:** Kidney transplantation; ABO incompatible; Antibody depletion; Immunosuppression; Desensitization protocols; Living donor transplantation

**Core tip:** This article demonstrates merits and demerits of ABO incompatible kidney transplantation (ABOi-KT). Although the excellent outcome of ABOi-KT has been achieved, unresolved matters still remain. We review the role of ABOi-KT for patients with end-stage kidney disease and considered validity whether ABOi-KT should be recommended as a therapeutic option of KT in the future.

Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatti C. ABO incompatible renal transplants: Good or bad?

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Kidney transplantation (KT) is known as a standard therapy for the patients with end-stage kidney disease (ESKD) and has been adopted widely in the world. However, living and deceased kidney donor pool does not resolve the shortage of transplantable organs**.** Different ways have been proposed to increase the donor pool and ABO incompatible KT (ABOi-KT) represents a valid source of organs to decrease the donor waiting list. ABOi-KT requires extra strategies and suffers extra risks across ABO blood type barrier compared to ABO compatible KT (ABOc-KT). ABOi-KT was previously considered to be contraindicated for many years. Presently, ABOi-KT has been accepted as a valid alternative therapy for ESKD and the outcome of ABOi-KT has become equivalent to ABOc-KT in adult and pediatric recipients [[1-4](#_ENREF_1)]. When a patient with ESKD requires KT and an acceptable living donor is ABO incompatible with the recipient, the patient can currently chose one of three options: (1) stay on the waiting list for deceased donor KT; (2) have paired kidney donor exchange (PKDE); or (3) undergo ABOi-KT.

According to the Organ Procurement and Transplantation Network (OPTN) report 2011, 86500 patients on the deceased donor waiting list, and almost 28000 were added to the list annually in the United States. Ten thousand patients received deceased donor KT, and 4900 patients received living KT. Almost 5000 patients died while waiting for a kidney. The median waiting time depended on the blood type of patients, but it is reported to be around 4 years for all patients on the OPTN report[[5](#_ENREF_5)]. Various reports analysing graft and patient survival related to the waiting time showed that 6 months or more of dialysis negatively affect the outcome[[6](#_ENREF_6), [7](#_ENREF_7)]. PKDE is an innovative method whereby 2 or more incompatible donor-recipient pairs exchange donors to create 2 or more compatible pairs. It is a very reasonable idea for human leukocyte antigen (HLA) sensitized and/or ABO incompatible patients. This primary idea was reported first by Rapaport in 1980’s[[8](#_ENREF_8)]. There are currently several variations of exchange such as three-way, four-way and domino paired donation [[9](#_ENREF_9)]. PKDE provides a recipient with an incompatible donor the chance to receive a compatible kidney, which is available by expanding the donor source and reducing the waiting time for deceased donor KT. Advantages of PKDE are low immunological risk, avoidance of intensified immunosuppression due to desensitization, and cost effectiveness[[10](#_ENREF_10)].

Alexandre *et al*[[11](#_ENREF_11)] demonstrated the ABOi-KT strategy using plasmapheresis and splenectomy to the break ABO barrier. Since then, this strategy has been a standard desensitization strategy of ABOi-KT for 20 years. ABOi-KT has become a common KT due to very few deceased donors in Japan, and ABOi-KT has accounted for approximately 30.0% of all living-donor KT[[12](#_ENREF_12)]. On the contrary, a tiny proportion, only 738 cases (0.94%) of ABOi-KT were performed between 1995 and 2010 in the United States[[4](#_ENREF_4)], but this number is increasing annually. The same trend continues in the United Kingdom, over the last decade, there has been an increase of ABOi-KT from less than 10 per year to 100 per year representing 1% of living donor performed[[13](#_ENREF_13)]. This increase is possibly due to the fact that protocols have been simplified over the years from complex surgical and pharmacological processes that variably may have involved splenectomy, rituximab (RIT), plasmapheresis and antibodies titration.

Although the use of ABOi-KT has increased worldwide, there are arguments against ABOi-KT as a universal treatment. To consider whether ABOi-KT is viable a therapeutic option for patients with ESKD, this review will focus on the transitional outcomes alongside current and future prospects in ABOi-KT.

**ABO ANTIGENSAND ANTIBODIES**

The concept of blood groups A, B and O (H) was established by Nobel laureate Karl Landsteiner in the early 1900s. These are polysaccharide antigens which are found in red cell, platelets, and other tissues such as endothelium[[14](#_ENREF_14)]. The antibodies to blood group antigen are isohemagglutinins and can be of either IgM or IgG type antibodies. However, for the purpose of this presentation IgG antibody is functionally relevant. Blood type A develops anti-B antibody, and blood type B has anti-A antibody. Blood type AB with A and B antigen has both antibodies, while Blood type O with both antibodies does not have any antigen. Blood type incompatibility means the exposure of A or B antigen to a person who has antibodies against these antigens. Therefore, these antigen expressions of an organ have been obstacles for ABOi-KT (Table 1). All blood type recipients accept a blood type O donor as a universal donor, and a blood type AB accepts all blood type donors as a universal recipient. Blood group type A, however, carries A1 or A2. The expression of A2 antigen is weaker than that of A1 antigen[[15](#_ENREF_15)]. The A2 subtype constitutes approximately 20% of blood type A in white races, while it is only 0.15% in Japanese population [[16](#_ENREF_16)]. A2 kidney may be less likely to suffer antibody rejection in the presence of anti-A antibody. In fact, non-A recipients receiving kidneys from A2 donors [[17](#_ENREF_17)], can universally and safely accept the transplantation without preconditioning at times of KT.

**HISTORY**

***Splenectomy, rituximab and no B cell depletion***

Previous clinical studies related to ABOi-KT are summarized in Table 2[[1-4](#_ENREF_1), [11](#_ENREF_11), [18-42](#_ENREF_18)]. The first successful report of ABOi-KT is dated back to 1987 when authors achieved long-term allograft survival in a series of 23 patients[[11](#_ENREF_11)]. Plasmapheresis and splenectomy were performed to reduce anti-blood type A or B (anti-A/B) antibody and to minimize the risk of hyperacute humoral rejection. Most of the modern desensitization protocols of ABOi-KT have been derived from their procedure and have since evolved. Their work was further greatly expanded in Japan due to the shortage of deceased donors with successful outcomes in ABOi-KT[[2](#_ENREF_2)].

Nowadays, splenectomy has been totally abandoned and the various desensitization protocols in use are combinations of antibody removal by plasmapheresis or immunoadsorption (IA), intravenous immunoglobulin (IVIG) to neutralize preformed antibodies, B lymphocyte depletion by anti-CD20 monoclonal antibody (RIT) and standard triple immunosuppression (calcineurin inhibitor, CNI; mycophenolate mofetil, MMF; and steroid). Recently, some authors reported successful outcomes of ABOi-KT without RIT and splenectomy[[35](#_ENREF_35), [42](#_ENREF_42), [43](#_ENREF_43)].

**ABOi-KT PREOPERATIVE MANAGEMENT**

Current strategies of ABOi-KT compose three common principles: (1) antibody measurement; (2) B-Cell depletion; (3) antibody depletion.

***Antibody measuremnt***

Assessment of anti-A/B antibody titer is crucial in ABOi-KT. It guides the effectiveness of operative preconditioning and determines the period to permit transplantation. In addition, posttransplant monitoring helps early detection of antibody-mediated rejection (AMR) by antibody rebound.

There are various measurement methods of anti-A/B titer, the most common used are tube technique, gel technique and flow cytometry[[44-48](#_ENREF_44)]. Although each center uses their familiar technique, there is a discrepancy of measured titer level. Kobayashi *et al*[[46](#_ENREF_46)] surveyed the differences of anti-A/B titers from the same blood samples which were measured by tube test in 29 Japanese centers. It was revealed that inter-institutional differences were 1:8 to 1:32 in IgM and 1:16 to 1:256 in IgG, because of low reproducibility by visual observation. Therefore, they concluded standardized measurement should be necessary. Kumlien *et al*[[47](#_ENREF_47)] analyzed the same blood samples in three centers. They also pointed out an inter-center variation of titer level using tube technique and suggested that gel technique is more reproducible than tube technique. Flow cytometry showed excellent reproducible compared with other techniques and would be suitable for the accurate measurement[[48](#_ENREF_48)]. However, this technique is not available in all centers due to the expensive equipment required.

High anti-A/B IgG titers preoperative are associated with poor long-term allograft survival in ABOi-KT[[49](#_ENREF_49)]. Gloor *et al*[[50](#_ENREF_50)] showed preoperative high anti-A/B IgG titers is the predictor for AMR, and the rapid increasing of titers is also associated with AMR and graft loss. In addition, Tobin *et al*[[51](#_ENREF_51)] also demonstrated that AMR was also associated with high titer at 1-2 wk posttransplant. Chung *et al*[[52](#_ENREF_52)] described there was no statistically significant difference between high- (> 1:256) and low-titer (< 1:128) at the baseline in allograft function at 6 mo after transplantation. Therefore, appropriate monitoring of anti-A/B titer is essential before and after ABOi-KT. Although anti-A/B antibody titer has to be measured during the early period after ABOi-KT due to the risk of AMR, but how long the monitoring should be continued remains unclear. Preoperative titer should be low in ABOi-KT, but the acceptable titer of anti-A/B antibody at the time of transplant has varied between 1:4 and 1:32 in line with the protocol of individual centers[[1](#_ENREF_1), [30-43](#_ENREF_30), [53-55](#_ENREF_53)]. After the ABO incompatible transplant necessitating initiation of antibody-depletion procedures, the level of anti-ABO antibody titer must be monitored to detect rebound in the serum antibody production.

***B-cell depletion***

**Splenectomy:** Splenectomy was considered a prerequisite for desensitization protocol in ABOi-KT after Alexandre *et al*[[11](#_ENREF_11)] reported that it reduced the risk of AMR. The principle of splenectomy was based on the concept that spleen is reservoir of antibody producing B-cells and antibody-producing plasma cells in the body. However, the efficacy of splenectomy in ABOi-KT is debatable, because severe AMR sometimes still occurs after splenectomy. The effect of splenectomy on the immune system is permanent. Following splenectomy the patients are at risk for the development of life-threatening sepsis, especially from encapsulated bacteria and they require life-long antibiotic prophylaxis. Splenectomy can lead to surgical complications such as hemorrhage, pancreatic injury, pancreatic leakage , and portal vein thrombosis[[56](#_ENREF_56)].

A comparative analysis of splenectomized recipients compared with RIT treated but without splenectomy, showed no statistically significant difference in the anti-A/B titer of KT and liver transplantation[[57](#_ENREF_57), [58](#_ENREF_58)]. It was concluded that splenectomy was not an essential prerequisite treatment in ABOi-KT. Although splenectomy has been replaced with RIT, Locke *et al*[[59](#_ENREF_59)] reported that splenectomy could be useful as salvage treatment for severe AMR secondary to anti-HLA antibody. Current consensus states that splenectomy is not necessary for the induction of ABOi-KT.

**Rituximab:** Splenectomy has been largely replaced by RIT in ABOi-KT protocols to remove B-cell. RIT is an anti-CD20 monoclonal antibody, which binds to CD20 on immature and mature B-cell resulting in depletion of B cell. RIT was originally developed for the treatment of non-Hodgkin’s lymphoma[[60](#_ENREF_60)]. RIT has been used extensively in the treatment of patients with autoimmune diseases and KT besides hematological malignancies[[61](#_ENREF_61)]. Adverse events related to B-cell depletion by RIT include fever, chill, headache, and nausea[[60](#_ENREF_60)], whilst serious cardiovascular and pulmonary events are rare[[61](#_ENREF_61)].

In the field of KT, RIT has been used as part of desensitization protocols in ABO- and HLA-incompatible KT, treatment of AMR, post-transplant lymphoproliferative disorder, and recurrent nephrotic syndrome[[62](#_ENREF_62)]. In the first experience of RIT use in ABOi-KT recipients, Sawada *et al*[[63](#_ENREF_63)] tried RIT, splenectomy, and double-filtration plasmapheresis (DFPP) for A1 to O ABOi-KT with persistent high anti-A antibody titer. The dosage of RIT was 375 mg/m2 per week for 4 wk pretransplant and there was no rebound of the titer after transplantation. Tyden *et al*[[64](#_ENREF_64)] succeeded with 4 ABO incompatible recipients using RIT and antigen-specific IA (IAs) with standard immunosuppression, without splenectomy. In their protocol, RIT (375 mg/m2) was administered once 10 d prior to transplant which was enough to deplete peripheral B-cell. Moreover, its effect was long-active for at least 12 mo without any serious side effects. After these successful reports were published, RIT has replaced splenectomy in desensitization protocol. Recently, some have tried low dose of RIT or even omitting it in ABOi-KT protocol to avoid over-immunosuppression without compromising excellent outcomes[[35](#_ENREF_35), [42](#_ENREF_42), [43](#_ENREF_43), [55](#_ENREF_55)].

Twenty-seven recipients who were diagnosed with steroid-resistant cell-mediated rejection or AMR received a single dose of RIT (375 mg/m2) as a salvage treatment[[65](#_ENREF_65)], twenty-four (88.9%) among these improved renal function. Serum creatinine decreased from mean 5.6 mg/dL before the treatment to mean 0.95 mg/dL after the treatment. RIT is useful to not only in AMR, but also in chronic antibody-mediated rejection (CAMR) prevention. Kohei *et al*[[66](#_ENREF_66)] observed that ABOi-KT with RIT had a statistically significant lower rate of CAMR at 2 years posttransplant than living ABOc-KT (3.5% *vs* 28.9%). However, this beneficial effect of RIT needs independent verification.

***Antibody depletion***

The antibody depletion treatments are the basis of ABOi-KT. In order to eliminate existing anti-A/B antibody, plasma exchange (PE), DFPP, and IA[[67](#_ENREF_67)] are available. They differ in their mechanisms of action, specificity, efficiency and cost.

In PE, recipient plasma is removed and replaced by human albumin, colloid solutions, and/or fresh frozen plasma (FFP). It has been widely used around the world as antibody removal in ABOi-KT. This method is simple, but it has several disadvantages compared with more specific techniques. Because of non-selective apheresis, PE removes not only anti-A/B antibody, but also coagulation factors and anti-viral/-bacterial immunoglobulin. Consequently, the risk of bleeding and infection is increased. FFP is generally needed for the last session before KT to prevent these complications. Other complications were reported by Tobian *et al*[[68](#_ENREF_68)]. In all PE sessions (*n* = 512), the total rate of complications was 15.4%. The most common complication was hypocalcaemia (6.8%), followed by urticaria or pruritus (4.3%), hypotention (2.9%) and nausea or vomiting (1.2%).

DFPP is designed to remove selectively the immunoglobulin from plasma and requires less substitution fluid compared to PE. When plasma separated by a first filter is passed through a second filter, IgG and IgM are filtered out and discarded. By single DFPP, 70% of IgM and 60% of IgG were removed and a one-fold titer reduction of anti-A/B antibody was observed[[69](#_ENREF_69)]. This technique also avoids the loss of coagulation factors and albumin unlike PE. However, significant amounts of albumin are lost by DFPP, and almost always albumin is needed as the replacement fluid. DFPP is also removes variable amount of fibrinogen[[70](#_ENREF_70)], and its measurement is necessary to avoid bleeding complication.

IA can be A/B antigen IAs or A/B non-antigen IAns (non-specific/semi-selective immunoadsorption) respectively if it removes only a specific antibody such as anti-A/B antibody or removes non antigen specific immunoglobulin. Between the two techniques IAs is most utilized method in ABO incompatible setting. On the other hand, IAns is suitable for the elimination of HLA antigens and it is most used in HLA incompatible/ABOi KT recipients. In IAs, the plasma is processed through an ABO immunoadsorbent column, which is coated with either blood type A or B antigens and allow selective removal of anti-A or B antibody, and the processed plasma is re-infused into the patient. Volume replacement is not necessary. IAs is selective and free from side effects of PE and DFPP. Single IAs reduces 2- to 4-fold titer between pre- and post-IAs, and at least four preoperative IAs are usually needed to obtain an acceptable titer at the expense of increased cost compared to PE and DFPP[[67](#_ENREF_67)]. IAs is generally safer and more effective, and therefore normally preferred. However, ultimate choice depends on each center’s decision, based on the availability of infrastructure and skill mix of staff.

**USE OF IVIG**

IVIG’s recognized immunomodulatory properties have been employed for the treatment of autoimmune diseases[[71](#_ENREF_71)]. IVIG is believed to act through various mechanisms: (1) complement down-regulation; (2) interactions with the Fc receptors; (3) inhibit of B/T-cell proliferation; (4) inhibit of CD8 T-cell cytotoxicity; and (5) increased apoptosis of B-cell[[71-73](#_ENREF_71)]. Mild and early adverse effects of IVIG include headache, chill, nausea, fatigue, myalgia, arthralgia, chest pain, back pain, and elevated blood pressure[[74](#_ENREF_74), [75](#_ENREF_75)]. However, rare but serious delayed adverse effects include renal toxicity, thromboembolic events (cerebrovascular accident and deep venous thrombosis), neurological toxicity (aseptic meningitis), hematological toxicity (neutropenia), and dermatological toxicity[[76](#_ENREF_76)]. The administration of high dose IVIG can cause hemolysis by anti-A/B antibody within the IVIG[[77](#_ENREF_77)]. In ABOi-KT, it is preferable if possible to use IVIG with low anti-A/B titer in order to avoid not only hemolysis but also AMR after transplantation due to anti-A/B titer elevation.

There is no uniformity in the dose IVIG used in the desensitization protocols of ABOi-KT[[1](#_ENREF_1), [30-32](#_ENREF_30), [34](#_ENREF_34), [35](#_ENREF_35), [37](#_ENREF_37), [38](#_ENREF_38), [40](#_ENREF_40), [43](#_ENREF_43), [54](#_ENREF_54), [78](#_ENREF_78)]. IVIG is usually administered after plasmapheresis, to reconstitute the natural levels of IgG. In the absence of control data, the use of IVIG in ABOi-KT can best be described as empirical.

**ACCOMMMDATION**

Without adequate anti-A/B antibody reduction and desensitization before KT, an incidence of AMR and irreversible damage cannot be avoided. Successful ABOi-KT requires the reduction of anti-A/B antibody titers against ABO antigens on the graft at the time of KT. However, anti-A/B antibody titer returns to the baseline level within almost 1 week after KT[[11](#_ENREF_11), [79](#_ENREF_79), [80](#_ENREF_80)], even if optimal desensitization is performed. Therefore, intense monitoring is necessary during critical first two weeks after ABOi-KT[[12](#_ENREF_12)]. Paradoxically, a phenomenon of accommodation is acquired in this term.

Accommodation is defined as a phenomenon whereby graft rejection is avoided despite reemergence of incompatible antibody. The mechanism was originally discovered in the field of xenotransplantation[[81](#_ENREF_81)], whereby endothelial cell was avoided against posttransplant humoral injury, possibly due to changes of antibody specificity, avidity, affinity and alteration of the antigen structure. This phenomenon is allegedly responsible for normal graft function and structure despite reemergence of anti-A/B antibody against incompatible A or B antigen in the graft[[82](#_ENREF_82)]. However, it is fair to accept that mechanism as well as the very existence of accommodation remains speculative.

**CURRENT PROTOCOL OF ABOi-KT**

In ABOi-KT, intensified immunosuppressive protocol usually starts before KT in order to deplete anti-A/B incompatible antibody. Many centers have modified original successful protocol of ABOi-KT[[11](#_ENREF_11)]. The splenectomy-free protocols published in the last decade are summarized in Table 3[[1](#_ENREF_1), [30-32](#_ENREF_30), [34-43](#_ENREF_34), [53-55](#_ENREF_53), [78](#_ENREF_78)]. RIT has been adopted in the place of splenectomy by majorities of centers. However, the timing and dose of RIT administrated remains variable. RIT or splenectomy free protocols have successfully, used low dose IVIG after plasmapheresis. The basis of North Europe protocol is IAs followed by high dose IVIG. However, postoperative IAs is not performed routinely and its use is determined by antibody titers[[83](#_ENREF_83)]. Maintenance immunosuppressive agents are mostly triple agents which are CNI, MMF and steroid. Tacrolimus is the CNI of choice in these ABOi-KT protocols. MMF was taken 7-14 d pretransplant in order to inhibit antibody production. Some centers use a protocol without daclizumab, basiliximab or antithymocyte globulin, and report excellent outcomes results. Thus, it is controversial whether these clonal antibodies should be introduced in ABOi-KT or not. All protocols of ABOi-KT have resulted in satisfactory outcome in the absence of randomized control trials. It is impossible to select an ideal protocol fit for all purpose.

**MINIMIZE IMMUNOSUPPRESION**

ABOi-KT setting efforts have been made to minimize immunosuppression in order to reduce the long-term risk of over-immunosuppression[[84](#_ENREF_84), [85](#_ENREF_85)]. The long-term effect of steroid use remains unclear in ABOi-KT. Oettl *et al*[[86](#_ENREF_86)] described 11 ABOi-KT recipients with late steroid withdrawal. Six recipients showed biopsied proven acute rejection during or soon after steroid cessation. However, Galliford *et al*[[30](#_ENREF_30)] tried early steroid sparing protocol in 10 recipients. Prednisolone was maintained at 1 mg/kg until 3 d posttransplant. It was reduced to 0.5 mg/kg at 4 d posttransplant, and discontinued after 1 wk posttransplant. In this study, patient and graft survival were 100% at 1 year posttransplant. But, 3 patients experienced acute rejection within one month after transplantation.

**HISTOLOGICAL FINDINGS IN ABOI-KT**

In ABOi-KT, acute AMR by anti-A/B antibody is a well-recognized cause of early graft loss. Diagnosis of acute AMR needs C4d staining in peritubular capillary (PTC) presence of anti-donor antibodies[[87](#_ENREF_87), [88](#_ENREF_88)]. Morphologic changes are known as acute tubular necrosis, capillary and/or glomerular inflammation, and transmural arteritis and/or arterial fibrinoid change. C4d staining is the hallmark of humoral induced complement activation and like ABOc-KT was thought to be a useful indicator of AMR even in the setting of ABOi-KT[[89](#_ENREF_89)]. However, C4d deposition without AMR was seen in 85.7% of ABOi-KT at 3 months posttransplant[[90](#_ENREF_90)]. Setoguchi *et al*[[91](#_ENREF_91)] analyzed protocol biopsies of ABOc-KT and ABOi-KT. C4d expression of PTC was detected in 94% of ABOi-KT, whereas in only 11% of ABOc-KT. In protocol biopsies during stable allograft function, 80% of ABO incompatible grafts showed as C4d positive, while 74% of HLA incompatible grafts were C4d negative[[92](#_ENREF_92)]. These histological studies indicate that the detection of C4d alone in ABO incompatible graft does not indicate AMR and support a concept of accommodation in ABOi-KT. Therefore, AMR after ABOi-KT can only be diagnosed on the basis of morphological evidence, serological evidence and the clinical course.

Morphologically transplant glomerulopathy (TG) at 1 year after transplantation was reported as an indicator of poor outcome[[93](#_ENREF_93)]. ABOi-KT had more severe TG than ABOc-KT without HLA antibody at 1 year posttransplant[[94](#_ENREF_94)]. However, there were no differences in interstitial fibrosis, tubular atrophy, chronic vasculopathy and allograft function between both groups. In the absence of prior AMR, histological change at 1year posttransplant was mild irrespective of ABO compatibility. Moreover, prior AMR in ABOi-KT was associated with TG and interstitial fibrosis and not to arteriolar hyalinosis and chronic vasculopathy[[91](#_ENREF_91)]. Consequently, ABO incompatible grafts with TG and/or interstitial fibrosis had lower GFR at 1year after transplantation than those with normal histology.

**THE INCIDENTCE OF ACUTE CELLULAR AND ANTIBODY MEDIATED REJECTION IN ABOI-KT**

As previously described, the outcome of graft survival in ABOi-KT has been similar to ABOc-KT. However, there is an increased risk of AMR in ABOi-KT due to anti-A/B antibody. Protocol biopsies at 3 moposttransplant in ABOi-KT had a significantly higher incidence of AMR compared to ABOc-KT (17.9% *vs* 1.1%). However, there was a significant difference in the rate of acute cellular rejection between ABOi-KT and ABOc-KT (48.4% *vs* 35.7%)[[90](#_ENREF_90)]. In the acute lesion score based on Banff classification[[95](#_ENREF_95)], *t*2-3 and *g*2-3 following ABOi-KT was higher than that of ABOc-KT (*t*2-3: 42.9% *vs* 19.4%, *g*2-3: 28.6% *vs* 6.5%). Gloor *et al*[[94](#_ENREF_94)] described in the study of protocol biopsies at 1 year posttransplant that there was a significant difference in the incidence of acute rejection between ABOi-KT and ABOc-KT without HLA antibody (50.0% *vs* 13.6%). Acute rejection in ABOi-KT was mainly AMR (73.3%) as compared to ABOc-KT without HLA antibody (12.5%). Setoguchi *et al*[[91](#_ENREF_91)] also compared the histologic findings of protocol biopsies in 48 ABO incompatible and 133 compatible grafts. There was no difference in clinical and subclinical rejection between ABO incompatible and compatible grafts (clinical: 37.5% *vs* 25.6%, subclinical: 10.4% *vs* 15.0%). However, ABO incompatible grafts had a high incidence of AMR compared to ABO compatible grafts (27.0% *vs* 5.3%). Interestingly, rejection was detected in 34.7% and 10.5% at 1 and 6-12 mo after transplantation in ABOc-KT, but 15.0% and 30.0% in ABOi-KT. However, Wilpert *et al*[34] demonstrated that the rejection rates in ABOi-KT were similar to that in ABOc-KT. Acute cellular rejection was detected in 23.2% of ABOi-KT and in 22.5% of ABOc-KT. Acute AMR was shown in 4.7% of ABOi-KT, which was similar to ABOc-KT (5.0%).

**ADVERSE EFFECT OF ABOI-KT**

***Infection***

The improvement in ABOi-KT graft survival rate has come at the expense of increased posttransplant infection. The infection rate in ABOi-KT is significantly higher than in ABOc-KT (60% *vs* 29.8%)[[37](#_ENREF_37)]. The rates of infection including cytomegalovirus (CMV), herpes simplex virus, varicella zoster virus and BK virus (BKV) in ABOi-KT were also significantly higher than in ABOc-KT. The most common viral infection was BKV in 25% of ABOi-KT compared to only 8.5% of ABOc-KT. However, the incidences of rejection, graft survival rate and function of ABOi-KT patients were compatible with these of ABOc-KT patients. On the contrary, Genberg *et al*[[31](#_ENREF_31)] showed that there was no statistical difference in overall infection complications between ABOi-KT with RIT and living ABOc-KT (40% *vs* 63.3%). However, ABOi-KT patients who were treated with RIT, may have had different infection profiles. Grim *et al*[[96](#_ENREF_96)]retrospectively analyzed the incidence of posttransplant infection in HLA sensitized KT or ABOi-KT treated with RIT and compared to HLA sensitized KT without RIT. The acute rejection rate in RIT treated KT was similar to KT without RIT (40% *vs* 33%). However, posttransplant infection rate was 48.0% RIT with KT, but only 11.1% without RIT. Kamar *et al*[[97](#_ENREF_97)] reported that infection rate was 45.5% in KT with RIT which was similar to KT without RIT (53.9%). Bacterial, viral and fungial infection were observed 36.3%, 18.2% and 16.9% in KT with RIT, as against 31.6%, 34.3% and 5.32% in KT without RIT. Polyoma virus infection rate (64.3%) was relatively high in RIT. Moreover, infection related-death was significantly higher in RIT treated patients. This data ascertained that RIT associated with severe infection which causes death rather than an increased risk of infection. Other report confirmed earlier observation showing that the incidence of posttransplant infection in RIT-treated recipients was similar to RIT-untreated recipients (52.2% *vs* 40.2%)[[98](#_ENREF_98)]. However, as in earlier studies the incidences of CMV and BKV infection in RIT-treated recipients were higher than in non RIT-treated recipients (CMV: 16.4% *vs* 5.7%, BKV: 13.4% *vs* 8.0%).

***Malignancy***

It is generally accepted that immunosuppression is associated with an increased incidence of malignancy in KT recipients compared to the general population[[99](#_ENREF_99)]. However, several studies have demonstrated that ABOi-KT did not increase the risk of posttransplant malignancy compared with ABOc-KT. Yamamoto *et al*[[100](#_ENREF_100)] analyzed the risk of ABOi-KT compared to ABOc-KT retrospectively. ABOi-KT recipients were older than ABOc-KT recipients and all ABOi-KT recipients received splenectomy, in this study despite increased age and splenectomy[[101](#_ENREF_101), [102](#_ENREF_102)], there was no significant difference in the incidence of malignancy between ABOi-KT and ABOc-KT (4.8% and 4.2%). Similarly, Hall *et al*[[103](#_ENREF_103)] showed that 7 of 318 ABOi-KT recipients experienced posttransplant cancer. The incidence rate ratio (IRR) of cancer in ABOi-KT was identical to that in matched control ABOc-KT (IRR: 0.99). This limited data reassuring indicates that ABOi-KT is not associated with increasing incidence of malignancy after KT. Thus, the further analysis of long-term observations in ABOi-KT after RIT was administered is needed.

**COST OF ABOi-KT**

It is recognized that KT is cost-effective option over dialysis[[104-106](#_ENREF_104)]. The estimated cost for ABOi-KT over 20 years was $315600, which was approximately 15% lower than dialysis[[107](#_ENREF_107)]. ABOi-KT is more expensive than ABOc-KT because of requirement for desensitization and removal of anti-A/B antibody. The cost of ABOi-KT in the first 90 d posttransplant is $90300 compared to $52500 for ABOc-KT[[108](#_ENREF_108)]. The additional cost of ABOi-KT amounts to [€](http://en.wikipedia.org/wiki/Euro_sign)31948 for IAs, RIT, IVIG, and prolonged hospital stay[[31](#_ENREF_31)]. The cost of single IA is approximately [€](http://en.wikipedia.org/wiki/Euro_sign)4,340-1433[[40](#_ENREF_40)]. However, despite more expensive, ABOi-KT is still more cost-effectiveness than dialysis in the long-term better quality of life.

**CONCLUSION**

Since first ABOi-KT over 50 years ago, it has become the accepted source of KT. Reassuringly, despite lack of control trials in ABOi-KT, more than satisfactory outcome have been observed in adult and pediatric recipients, and in many studies equivalent to living ABOc-KT. ABOi-KT has also has disadvantages in spite of excellent outcome (Table 4). Preconditioning treatment of ABOi-KT, such as antibody reduction and desensitization, is more intensified and complicated than that of ABOc-KT. With current protocols, the occurrence of early graft loss and AMR are not completely abolished. Preconditioning strategy in ABOi-KT has evolved over time. RIT has replaced splenectomy which was once thought a crucial procedure for ABOi-KT. Even, RIT use is increasingly abandoned, and in favor of IAs and IVIG. Overall, ABOi-KT is more expensive than ABOc-KT which may restrict its adoption in resource poor countries. We believe that live donor ABOi-KT is a viable alternative to waiting on deceased donor list.

REFERENCE

1 **Tydén G**, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. *Pediatr Transplant* 2011; **15**: 502-504 [PMID: 21771231 DOI: 10.1111/j.1399-3046.2011.01480.x]

2 **Takahashi K**, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. *Am J Transplant* 2004; **4**: 1089-1096 [PMID: 15196066 DOI: 10.1111/j.1600-6143.2004.00464.x]

3 **Shishido S**, Hyodo YY, Aoki Y, Takasu J, Kawamura T, Sakai KK, Aikawa AA, Satou H, Muramatsu MM, Matsui Z. Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls. *Transplant Proc* 2012; **44**: 214-216 [PMID: 22310617 DOI: 10.1016/j.transproceed.2011.12.017]

4 **Montgomery JR**, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States. *Transplantation* 2012; **93**: 603-609 [PMID: 22290268 DOI: 10.1097/TP.0b013e318245b2af]

5 Organ Procurement and Transplantation Network. OPTN/SRTR 2011 Annual Data Report: kidney . http: //srtr.transplant.hrsa.gov/annual\_reports/2011/default.aspx

6 **Goldfarb-Rumyantzev A**, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK. Duration of end-stage renal disease and kidney transplant outcome. *Nephrol Dial Transplant* 2005; **20**: 167-175 [PMID: 15546892 DOI: 10.1093/ndt/gfh541]

7 **Meier-Kriesche HU**, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. *Transplantation* 2002; **74**: 1377-1381 [PMID: 12451234 DOI: 10.1097/01.TP.0000034632.77029.91]

8 **Rapaport FT**. The case for a living emotionally related international kidney donor exchange registry. *Transplant Proc* 1986; **18**: 5-9 [PMID: 11649919]

9 **Gentry SE**, Montgomery RA, Segev DL. Kidney paired donation: fundamentals, limitations, and expansions. *Am J Kidney Dis* 2011; **57**: 144-151 [PMID: 21184921 DOI: 10.1053/j.ajkd.2010.10.005]

10 **Segev DL**, Gentry SE, Warren DS, Reeb B, Montgomery RA. Kidney paired donation and optimizing the use of live donor organs. *JAMA* 2005; **293**: 1883-1890 [PMID: 15840863 DOI: 10.1001/jama.293.15.1883]

11 **Alexandre GP**, Squifflet JP, De Bruyère M, Latinne D, Reding R, Gianello P, Carlier M, Pirson Y. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. *Transplant Proc* 1987; **19**: 4538-4542 [PMID: 3321614]

12 **Takahashi K**, Saito K. ABO-incompatible kidney transplantation. *Transplant Rev (Orlando)* 2013; **27**: 1-8 [PMID: 22902167 DOI: 10.1016/j.trre.2012.07.003]

13 National Health System Blood and Trasnplant. Activity Report 2012-2013, kidney activity. http: //www.organdonation.nhs.uk/statistics/transplant\_activity\_report/

14 **Rydberg L**. ABO-incompatibility in solid organ transplantation. *Transfus Med* 2001; **11**: 325-342 [PMID: 11532188]

15 **Economidou J**, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites. *Vox Sang* 1967; **12**: 321-328 [PMID: 6067900]

16 **Thielke J**, Kaplan B, Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. *Semin Nephrol* 2007; **27**: 408-413 [PMID: 17616273 DOI: 10.1016/j.semnephrol.2007.03.003]

17 **Nelson PW**, Helling TS, Pierce GE, Ross G, Shield CF, Beck ML, Blake B, Cross DE. Successful transplantation of blood group A2 kidneys into non-A recipients. *Transplantation* 1988; **45**: 316-319 [PMID: 3278421]

18 **HUME DM**, MERRILL JP, MILLER BF, THORN GW. Experiences with renal homotransplantation in the human: report of nine cases. *J Clin Invest* 1955; **34**: 327-382 [PMID: 13233354 DOI: 10.1172/JCI103085]

19 **Starzl TE**, Marchioro TL, Holmes JH, Hermann G, Brittain RS, Stonington OH, Talmage DW, Waddell WR. Renal homografts in patients with major donor-recipient blood group incompatibilities. *Surgery* 1964; **55**: 195-200 [PMID: 14121762]

20 **Sheil AG**, Stewart JH, Tiller DJ, May J. ABO blood group incompatibility in renal transplantation. *Transplantation* 1969; **8**: 299-300 [PMID: 4908385 DOI: [10.1097/00007890-196909000-00028](http://dx.doi.org/10.1097/00007890-196909000-00028)]

21 **Ota K**, Takahashi K, Agishi T, Sonda T, Oka T, Ueda S, Amemiya H, Shiramizu T, Okazaki H, Akiyama N, Hasegawa A, Kawamura T, Takagi H, Ueno A. Multicentre trial of ABO-incompatible kidney transplantation. Japanese Biosynsorb ABO-incompatible kidney transplant study group. *Transpl Int* 1992; **5** Suppl 1: S40-S43 [PMID: 14628736]

22 **Tanabe K**, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, Koga S, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. *Transplantation* 1998; **65**: 224-228 [PMID: 9458019 DOI: [10.1097/00007890-199801270-00014](http://dx.doi.org/10.1097/00007890-199801270-00014)]

23 **Ishida H**, Koyama I, Sawada T, Utsumi K, Murakami T, Sannomiya A, Tsuji K, Yoshimura N, Tojimbara T, Nakajima I, Tanabe K, Yamaguchi Y, Fuchinoue S, Takahashi K, Teraoka S, Ito K, Toma H, Agishi T. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. *Transplantation* 2000; **70**: 681-685 [PMID: 10972229 DOI: [10.1097/00007890-200008270-00024](http://dx.doi.org/10.1097/00007890-200008270-00024)]

24 **Ohta T**, Kawaguchi H, Hattori M, Takahashi K, Nagafuchi H, Akioka Y, Mizushima W, Ishikawa N, Tanabe K, Toma H, Takahashi K, Ota K, Ito K. ABO-incompatible pediatric kidney transplantation in a single-center trial. *Pediatr Nephrol* 2000; **14**: 1-5 [PMID: 10654320]

25 **Shishido S**, Asanuma H, Tajima E, Hoshinaga K, Ogawa O, Hasegawa A, Honda M, Nakai H. ABO-incompatible living-donor kidney transplantation in children. *Transplantation* 2001; **72**: 1037-1042 [PMID: 11579297 DOI: [10.1097/00007890-200109270-00010](http://dx.doi.org/10.1097/00007890-200109270-00010)]

26 **Shimmura H**, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, Miyamoto N, Shirakawa H, Setoguchi K, Nakajima I, Fuchinoue S, Teraoka S, Toma H. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. *Transplantation* 2005; **80**: 985-988 [PMID: 16249749 DOI: [10.1097/01.tp.0000173647.43616.78](http://dx.doi.org/10.1097/01.tp.0000173647.43616.78)]

27 **Futagawa Y**, Terasaki PI. ABO incompatible kidney transplantation - an analysis of UNOS Registry data. *Clin Transplant* ; **20**: 122-126 [PMID: 16556166 DOI: 10.1111/j.1399-0012.2005.00452.x]

28 **Ishida H**, Miyamoto N, Shirakawa H, Shimizu T, Tokumoto T, Ishikawa N, Shimmura H, Setoguchi K, Toki D, Iida S, Teraoka S, Takahashi K, Toma H, Yamaguchi Y, Tanabe K. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation--single center analysis. *Am J Transplant* 2007; **7**: 825-831 [PMID: 17250557 DOI: 10.1111/j.1600-6143.2006.01676.x]

29 **Tydén G**, Donauer J, Wadström J, Kumlien G, Wilpert J, Nilsson T, Genberg H, Pisarski P, Tufveson G. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. *Transplantation* 2007; **83**: 1153-1155 [PMID: 17496528 DOI: 10.1097/01.tp.0000262570.18117.55]

30 **Galliford J**, Charif R, Chan KK, Loucaidou M, Cairns T, Cook HT, Dorling A, Hakim N, McLean A, Papalois V, Malde R, Regan F, Redman M, Warrens AN, Taube D. ABO incompatible living renal transplantation with a steroid sparing protocol. *Transplantation* 2008; **86**: 901-906 [PMID: 18852653 DOI: 10.1097/TP.0b013e3181880c0f]

31 **Genberg H**, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. *Transplantation* 2008; **85**: 1745-1754 [PMID: 18580466 DOI: 10.1097/TP.0b013e3181726849]

32 **Oettl T**, Halter J, Bachmann A, Guerke L, Infanti L, Oertli D, Mihatsch M, Gratwohl A, Steiger J, Dickenmann M. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. *Nephrol Dial Transplant* 2009; **24**: 298-303 [PMID: 18728155 DOI: 10.1093/ndt/gfn478]

33 **Toki D**, Ishida H, Setoguchi K, Shimizu T, Omoto K, Shirakawa H, Iida S, Horita S, Furusawa M, Ishizuka T, Yamaguchi Y, Tanabe K. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. *Am J Transplant* 2009; **9**: 567-577 [PMID: 19260836 DOI: 10.1111/j.1600-6143.2008.02538.x]

34 **Wilpert J**, Fischer KG, Pisarski P, Wiech T, Daskalakis M, Ziegler A, Neumann-Haefelin E, Drognitz O, Emmerich F, Walz G, Geyer M. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. *Nephrol Dial Transplant* 2010; **25**: 3778-3786 [PMID: 20466677 DOI: 10.1093/ndt/gfq229]

35 **Flint SM**, Walker RG, Hogan C, Haeusler MN, Robertson A, Francis DM, Millar R, Finlay M, Landgren A, Cohney SJ. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. *Am J Transplant* 2011; **11**: 1016-1024 [PMID: 21449947 DOI: 10.1111/j.1600-6143.2011.03464.x]

36 **Fuchinoue S**, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, Koyama I, Kubota K, Tojimbara T, Nakajima I, Teraoka S. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. *Transplantation* 2011; **91**: 853-857 [PMID: 21297552 DOI: 10.1097/TP.0b013e31820f08e8]

37 **Habicht A**, Bröker V, Blume C, Lorenzen J, Schiffer M, Richter N, Klempnauer J, Haller H, Lehner F, Schwarz A. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. *Nephrol Dial Transplant* 2011; **26**: 4124-4131 [PMID: 21622990 DOI: 10.1093/ndt/gfr215]

38 **Lipshutz GS**, McGuire S, Zhu Q, Ziman A, Davis R, Goldfinger D, Reed EF, Wilkinson AH, Danovitch GM, Pham PT. ABO blood type-incompatible kidney transplantation and access to organs. *Arch Surg* 2011; **146**: 453-458 [PMID: 21502455 DOI: 10.1001/archsurg.2011.40]

39 **Shirakawa H**, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, Tanabe K. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. *Clin Transplant* 2011; **25**: 878-884 [PMID: 21175849 DOI: 10.1111/j.1399-0012.2010.01384.x]

40 **Morath C**, Becker LE, Leo A, Beimler J, Klein K, Seckinger J, Kihm LP, Schemmer P, Macher-Goeppinger S, Wahrmann M, Böhmig GA, Opelz G, Süsal C, Zeier M, Schwenger V. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. *Transplantation* 2012; **93**: 827-834 [PMID: 22382504 DOI: 10.1097/TP.0b013e31824836ae]

41 **Uchida J**, Kuwabara N, Machida Y, Iwai T, Naganuma T, Kumada N, Nakatani T. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience. *Transplant Proc* 2012; **44**: 204-209 [PMID: 22310615 DOI: 10.1016/j.transproceed.2011.11.006]

42 **Ashimine S**, Watarai Y, Yamamoto T, Hiramitsu T, Tsujita M, Nanmoku K, Goto N, Takeda A, Katayama A, Uchida K, Kobayashi T. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. *Kidney Int* 2014; **85**: 425-430 [PMID: 23945498 DOI: 10.1038/ki.2013.291]

43 **Montgomery RA**, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M. ABO incompatible renal transplantation: a paradigm ready for broad implementation. *Transplantation* 2009; **87**: 1246-1255 [PMID: 19384174 DOI: 10.1097/TP.0b013e31819f2024]

44 **Stussi G**, Huggel K, Lutz HU, Schanz U, Rieben R, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. *Br J Haematol* 2005; **130**: 954-963 [PMID: 16156865 DOI: 10.1111/j.1365-2141.2005.05705.x]

45 **Lindberg L**, Johansson SM, Liu J, Grufman P, Holgersson J. Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B? *Transfusion* 2011; **51**: 494-503 [PMID: 20849404 DOI: 10.1111/j.1537-2995.2010.02870.x]

46 **Kobayashi T**, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. *Xenotransplantation* 2006; **13**: 136-140 [PMID: 16623808 DOI: 10.1111/j.1399-3089.2006.00296.x]

47 **Kumlien G**, Wilpert J, Säfwenberg J, Tydén G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. *Transplantation* 2007; **84**: S17-S19 [PMID: 18162980 DOI: 10.1097/01.tp.0000296019.85986.af]

48 **Tanabe K**. Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey. *Transplantation* 2007; **84**: S13-S16 [PMID: 18162979 DOI: 10.1097/01.tp.0000296018.82857.ef]

49 **Shimmura H**, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. *Transplantation* 2000; **70**: 1331-1335 [PMID: 11087148]

50 **Gloor JM**, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. *Transplantation* 2003; **75**: 971-977 [PMID: 12698082 DOI: 10.1097/01.TP.0000058226.39732.32]

51 **Tobian AA**, Shirey RS, Montgomery RA, Cai W, Haas M, Ness PM, King KE. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. *Am J Transplant* 2010; **10**: 1247-1253 [PMID: 20420632 DOI: 10.1111/j.1600-6143.2010.03103.x]

52 **Chung BH**, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, Kim JI, Moon IS, Choi BS, Park CW, Kim YS, Yang CW. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. *Ren Fail* 2011; **33**: 150-158 [PMID: 21332336 DOI: 10.3109/0886022x.2011.552149]

53 **Saito K**, Nakagawa Y, Suwa M, Kumagai N, Tanikawa T, Nishiyama T, Ueno M, Gejyo F, Nishi S, Takahashi K. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. *Xenotransplantation* 2006; **13**: 111-117 [PMID: 16623803 DOI: 10.1111/j.1399-3089.2006.00277.x]

54 **Tydén G**, Kumlien G, Genberg H, Sandberg J, Sedigh A, Lundgren T, Gjertsen H, Fehrman I. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. *Xenotransplantation* 2006; **13**: 105-107 [PMID: 16623801 DOI: 10.1111/j.1399-3089.2006.00292.x]

55 **Chikaraishi T**, Sasaki H, Tsutsumi H, Miyano S, Nakazawa R, Nakano T, Kitajima K, Kudo H, Takahashi T, Sato Y, Kimura K. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab. *Transplant Proc* 2008; **40**: 3445-3447 [PMID: 19100409 DOI: 10.1016/j.transproceed.2008.06.110]

56 **Cadili A**, de Gara C. Complications of splenectomy. *Am J Med* 2008; **121**: 371-375 [PMID: 18456028 DOI: 10.1016/j.amjmed.2008.02.014]

57 **Gloor JM**, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, Kremers WK, Stegall MD. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. *Transplantation* 2005; **80**: 1572-1577 [PMID: 16371928]

58 **Raut V**, Mori A, Kaido T, Ogura Y, Taku I, Nagai K, Sasaki N, Endo K, Hata T, Yagi S, Egawa H, Uemoto S. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. *Transplantation* 2012; **93**: 99-105 [PMID: 22094955 DOI: 10.1097/TP.0b013e318239e8e4]

59 **Locke JE**, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, Segev DL, Montgomery RA. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. *Am J Transplant* 2007; **7**: 842-846 [PMID: 17391127 DOI: 10.1111/j.1600-6143.2006.01709.x]

60 **Maloney DG**, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. *Blood* 1994; **84**: 2457-2466 [PMID: 7522629]

61 **Pescovitz MD**. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. *Am J Transplant* 2006; **6**: 859-866 [PMID: 16611321 DOI: 10.1111/j.1600-6143.2006.01288.x]

62 **Becker YT**, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. *Transpl Int* 2006; **19**: 621-628 [PMID: 16827678 DOI: 10.1111/j.1432-2277.2006.00345.x]

63 **Sawada T**, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. *Transplantation* 2002; **74**: 1207-1210 [PMID: 12451255 DOI: 10.1097/01.tp.0000040990.15896.76]

64 **Tydén G**, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. *Transplantation* 2003; **76**: 730-731 [PMID: 12973118 DOI: 10.1097/01.tp.0000078622.43689.d4]

65 **Becker YT**, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. *Am J Transplant* 2004; **4**: 996-1001 [PMID: 15147435 DOI: 10.1111/j.1600-6143.2004.00454.x]

66 **Kohei N**, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. *Am J Transplant* 2012; **12**: 469-476 [PMID: 22054413 DOI: 10.1111/j.1600-6143.2011.03830.x]

67 **Tydén G**, Kumlien G, Efvergren M. Present techniques for antibody removal. *Transplantation* 2007; **84**: S27-S29 [PMID: 18162984 DOI: 10.1097/01.tp.0000296102.94695.c0]

68 **Tobian AA**, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. *Transfusion* 2009; **49**: 1248-1254 [PMID: 19210321 DOI: 10.1111/j.1537-2995.2008.02085.x]

69 **Tanabe K**. Double-filtration plasmapheresis. *Transplantation* 2007; **84**: S30-S32 [PMID: 18162985 DOI: 10.1097/01.tp.0000296103.34735.b8]

70 **Nakanishi T**, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis. *Clin Exp Nephrol* 2013; : [PMID: 23887747 DOI: 10.1007/s10157-013-0838-0]

71 **Kazatchkine MD**, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. *N Engl J Med* 2001; **345**: 747-755 [PMID: 11547745 DOI: 10.1056/NEJMra993360]

72 **Glotz D**, Antoine C, Julia P, Pegaz-Fiornet B, Duboust A, Boudjeltia S, Fraoui R, Combes M, Bariety J. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. *Transpl Int* 2004; **17**: 1-8 [PMID: 14685653 DOI: 10.1007/s00147-003-0674-3]

73 **Jordan S**, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. *Am J Transplant* 2003; **3**: 653-664 [PMID: 12780556]

74 **Ryan ME**, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. *Clin Pediatr (Phila)* 1996; **35**: 23-31 [PMID: 8825847]

75 **Stangel M**, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. *Clin Neuropharmacol* 1997; **20**: 385-393 [PMID: 9331514]

76 **Orbach H**, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. *Clin Rev Allergy Immunol* 2005; **29**: 173-184 [PMID: 16391392 DOI: 10.1385/criai: 29: 3: 173]

77 **Kahwaji J**, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. *Clin J Am Soc Nephrol* 2009; **4**: 1993-1997 [PMID: 19833910 DOI: 10.2215/CJN.04540709]

78 **Sivakumaran P**, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, Klapper EB. Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. *J Clin Apher* 2009; **24**: 155-160 [PMID: 19658162 DOI: 10.1002/jca.20206]

79 **Reding R**, Squifflet JP, Pirson Y, Jamart J, De Bruyère M, Moriau M, Latinne D, Carlier M, Alexandre GP. Living-related and unrelated donor kidney transplantation: comparison between ABO-compatible and incompatible grafts. *Transplant Proc* 1987; **19**: 1511-1513 [PMID: 3274365]

80 **Aikawa A**, Hadano T, Ohara T, Hasegawa A, Yamashita M, Shindo M, Mizuiri T, Fushimi T, Sakai K, Hirayama N, Arai K, Tajima E. Relation between ABO blood type antigen and antibody and acute vascular rejection in ABO incompatible kidney transplantation. *Transplant Proc* 1998; **30**: 3507-3509 [PMID: 9838538]

81 **Platt JL**, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH. Transplantation of discordant xenografts: a review of progress. *Immunol Today* 1990; **11**: 450-46; discussion 450-46; [PMID: 2073317]

82 **Park WD**, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. *Am J Transplant* 2003; **3**: 952-960 [PMID: 12859529]

83 **Geyer M**, Donauer J, Pisarski P, Drognitz O, Schulz-Huotari C, Wisniewski U, Gropp A, Göbel H, Gerke P, Teschner S, Walz G, Wilpert J. Preemptive postoperative antigen-specific immunoadsorption in ABO-incompatible kidney transplantation: necessary or not? *Transplantation* 2007; **84**: S40-S43 [PMID: 18162989 DOI: 10.1097/01.tp.0000296021.72977.3b]

84 **Lightner A**, Concepcion W, Grimm P. Steroid avoidance in renal transplantation. *Curr Opin Organ Transplant* 2011; **16**: 477-482 [PMID: 21844809 DOI: 10.1097/MOT.0b013e32834a8c74]

85 **Flechner SM**, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. *Clin Transplant* 2008; **22**: 1-15 [PMID: 18217899 DOI: 10.1111/j.1399-0012.2007.00739.x]

86 **Oettl T**, Zuliani E, Gaspert A, Hopfer H, Dickenmann M, Fehr T. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection. *Transplantation* 2010; **89**: 702-706 [PMID: 20010328 DOI: 10.1097/TP.0b013e3181c9cc67]

87 **Racusen LC**, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. *Clin J Am Soc Nephrol* 2006; **1**: 415-420 [PMID: 17699240 DOI: 10.2215/CJN.01881105]

88 **Sis B**, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. *Am J Transplant* 2010; **10**: 464-471 [PMID: 20121738 DOI: 10.1111/j.1600-6143.2009.02987.x]

89 **Fidler ME**, Gloor JM, Lager DJ, Larson TS, Griffin MD, Textor SC, Schwab TR, Prieto M, Nyberg SL, Ishitani MB, Grande JP, Kay PA, Stegall MD. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. *Am J Transplant* 2004; **4**: 101-107 [PMID: 14678040]

90 **Ushigome H**, Okamoto M, Koshino K, Nobori S, Okajima H, Masuzawa N, Urasaki K, Yoshimura N. Findings of graft biopsy specimens within 90 d after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation. *Clin Transplant* 2010; **24** Suppl 22: 16-21 [PMID: 20590688 DOI: 10.1111/j.1399-0012.2010.01278.x]

91 **Setoguchi K**, Ishida H, Shimmura H, Shimizu T, Shirakawa H, Omoto K, Toki D, Iida S, Setoguchi S, Tokumoto T, Horita S, Nakayama H, Yamaguchi Y, Tanabe K. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. *Am J Transplant* 2008; **8**: 86-94 [PMID: 18021283 DOI: 10.1111/j.1600-6143.2007.02036.x]

92 **Haas M**, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, Simpkins CE, Warren DS, King KE, Zachary AA, Montgomery RA. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. *Am J Transplant* 2006; **6**: 1829-1840 [PMID: 16889542 DOI: 10.1111/j.1600-6143.2006.01356.x]

93 **Cosio FG**, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. *Am J Transplant* 2005; **5**: 2464-2472 [PMID: 16162196 DOI: 10.1111/j.1600-6143.2005.01050.x]

94 **Gloor JM**, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. *Am J Transplant* 2006; **6**: 1841-1847 [PMID: 16780546 DOI: 10.1111/j.1600-6143.2006.01416.x]

95 **Racusen LC**, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; **55**: 713-723 [PMID: 9987096 DOI: 10.1046/j.1523-1755.1999.00299.x]

96 **Grim SA**, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, Clark NM. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. *Clin Transplant* 2007; **21**: 628-632 [PMID: 17845637 DOI: 10.1111/j.1399-0012.2007.00700.x]

97 **Kamar N**, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Rostaing L. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. *Am J Transplant* 2010; **10**: 89-98 [PMID: 19656128 DOI: 10.1111/j.1600-6143.2009.02785.x]

98 **Baek CH**, Yang WS, Park KS, Han DJ, Park JB, Park SK. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. *Nephron Extra* 2012; **2**: 66-75 [PMID: 22619669 DOI: 10.1159/000337339]

99 **Kasiske BL**, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. *Am J Transplant* 2004; **4**: 905-913 [PMID: 15147424 DOI: 10.1111/j.1600-6143.2004.00450.x]

100 **Yamamoto T**, Kawaguchi T, Watarai Y, Tujita M, Hiramitsu T, Nanmoku K, Goto N, Katayama A, Kobayashi T, Uchida K. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy. *Transplant Proc* 2012; **44**: 210-213 [PMID: 22310616 DOI: 10.1016/j.transproceed.2011.11.048]

101 **Danpanich E**, Kasiske BL. Risk factors for cancer in renal transplant recipients. *Transplantation* 1999; **68**: 1859-1864 [PMID: 10628765]

102 **Webster AC**, Wong G, Craig JC, Chapman JR. Managing cancer risk and decision making after kidney transplantation. *Am J Transplant* 2008; **8**: 2185-2191 [PMID: 18782291 DOI: 10.1111/j.1600-6143.2008.02385.x]

103 **Hall EC**, Engels EA, Montgomery RA, Segev DL. Cancer risk after ABO-incompatible living-donor kidney transplantation. *Transplantation* 2013; **96**: 476-479 [PMID: 23799426 DOI: 10.1097/TP.0b013e318299dc0e]

104 **Loubeau PR**, Loubeau JM, Jantzen R. The economics of kidney transplantation versus hemodialysis. *Prog Transplant* 2001; **11**: 291-297 [PMID: 11871278]

105 **Haller M**, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. *Nephrol Dial Transplant* 2011; **26**: 2988-2995 [PMID: 21310740 DOI: 10.1093/ndt/gfq780]

106 **Matas AJ**, Schnitzler M. Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. *Am J Transplant* 2004; **4**: 216-221 [PMID: 14974942]

107 **Schnitzler M**, Machnicki G. ABO-incompatible living donor transplantation: is it economically "compatible"? *Transplantation* 2006; **82**: 168-169 [PMID: 16858277 DOI: 10.1097/01.tp.0000226242.10027.e7]

108 **Schwartz J**, Stegall MD, Kremers WK, Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. *Transplantation* 2006; **82**: 155-163 [PMID: 16858274 DOI: 10.1097/01.tp.0000226152.13584.ae]

**P-Reviewers:** Shrestha BM, Saeed T **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Table 1 Combination of blood type and compatibility**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Donor** | | | |
|  |  | **A** | **B** | **O** | **AB** |
| Recipient | A | - | + | - | + |
| B | + | - | - | + |
| O | + | + | - | + |
| AB | - | - | - | - |
| +: ABO incompatibe transplantation; -: ABO compatible transplantation. | | | | |  |

**Table 2 Historical clinical reports in ABO incompatible kidney transplantation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Study population** | **ABOi population** | **Desensitization** | **Outcome** |
| Hume *et al*[18] | Observational | 9 | 1 | no treatment | Graft nephrectomy day 17 |
| Starzl *et al*[19] | Observational | 3 | 2 | SPx (1 case) | Graft survival 74 d (1 case), patient death day 24 (1case) |
| Sheil *et al*[20] | Observational | 2 | 2 | no tretment | Graft nephrectomy day 14 |
| Alexandre *et al*[11] | Observational | 23 | 23 | PE/SPx | 2-yr graft survival: 88% (related donor), 50% (unrelated donor) |
| Ota *et al*[21] | Observational, comparative | 51 | 51 | DFPP and/or IAs/SPx | 2-yr graft survival: 87% *vs* 84.6% *vs* 50% ( A- *vs* B- *vs* ABO-incompatible) |
| Tanabe *et al*[22] | Observational, comparative | 433 | 67 | DFPP and IAs/SPx | 8-yr graft survival: 73% *vs* 80 % (ABOi *vs* ABOc) |
| Ishida *et al*[23] | Observational | 93 | 93 | DFPP/SPx | 5-yr graft survival: 73% |
| Ohta *et al*[24] | Observational, pediatric | 10 | 10 | DFPP or PE or IAs/SPx | 5.4-yr graft survival: 100% |
| Shishido *et al*[25] | Observational, pediatric | 16 | 16 | PE and IAs/SPx | 5-yr graft survival: 85% |
| Takahashi *et al*[2] | Observational, comparative | 1496 | 441 | DFPP or PE or IAs/SPx | 9-yr graft survival: 59% *vs* 57% (ABOi *vs* ABOc) |
| Shimmura *et al*[26] | Observational, comparative | 167 | 167 | DFPP and/or IAs/SPx | 5-yr graft survival: 74.3% *vs* 78.5% ( CYA with AZ or MZ *vs* TAC or MMF) |
| Futagawa *et al*[27] | Observational, comparative | 37803 | 191 | NA | 5-yr graft survival: 66.2% *vs* 79.5% (ABOi *vs* ABOc) |
| Ishida *et al*[28] | Observational, comparative | 222 | 222 | DFPP/SPx | 5-yr graft survival: 73% *vs* 90% ( CYA with AZ *vs* TAC with MMF) |
| Tyden *et al*[29] | Observational, comparative | 334 | 60 | IAs/RIT/IVIG | Graft survival: ABOi 97% (1.5-yr) *vs* ABOc 95% (1.8-yr) |
| Galliford *et al*[30] | Observational | 10 | 10 | PE/RIT/IVIG | 1-yr graft survival: 100% |
| Genberg *et al*[31] | Observational, comparative | 45 | 15 | IAs/RIT/IVIG | Graft survival: ABOi 86.7% (3.4-yr) *vs* ABOc 86.7% (4.0-yr) |
| Oettl *et al*[32] | Observational | 10 | 10 | IAs/RIT/IVIG | 1.3-yr graft survival: 100% |
| Toki *et al*[33] | Observational, comparative | 57 | 57 | DFPP/SPx | 8-yr graft survival: 49% *vs* 95% (AMMR *vs* non-AMMR) |
| Wilpert *et al*[34] | Observational, comparative | 83 | 40 | IAs/RIT/IVIG | Graft survival: ABOi 100% (3.3-yr) *vs* ABOc 93% (1.5-yr) |
| Tyden *et al*[1] | Observational, comparative, pediatric | 38 | 10 | IAs/RIT/IVIG | Graft loss within 3 years: ABOi 1 case, ABOc 2 cases |
| Flint *et al*[35] | Observational, comparative | 89 | 37 | PE/IVIG | 1-yr graft survival: 100% (ABOi *vs* ABOc) |
| Fichinoue *et al*[36] | Observational, comparative | 393 | 113 | DFPP or PE/SPx or RIT | 5-yr graft survival: 88.4% *vs* 90.3% *vs* 100% (ABOc *vs* ABOi-SPx *vs* ABOi-RIT) |
| Habicht *et al*[37] | Observational, comparative | 68 | 21 | IAs/RIT/IVIG | 1-yr graft survival : 100% (ABOi *vs* ABOc) |
| Lipshutz *et al*[38] | Observational | 18 | 18 | PE/RIT/IVIG | 1-yr graft survival: 94.4% |
| Shirakawa *et al*[39] | Observational, comparative | 74 | 74 | DFPP/RIT | 1-yr graft survival: 95.7% *vs* 98.% ( RIT 500mg *vs* RIT 200mg) |
| Shishido *et al*[3] | Observational, comparative, pediatric | 323 | 52 | PE/SPx or RIT | 15-yr graft survival: 86% *vs* 78% (ABOi *vs* ABOc) |
| Montgmery *et al*[4] | Observational, comparative | 78193 | 738 | NA | 10-yr cumulative incidence of graft loss: 27.1% *vs* 23.9% (ABOi *vs* ABOc) |
| Morath *et al*[40] | Observational, comparative | 19 | 19 | IAs or IAns/RIT/IVIG | 1-yr graft survival: 100% (IAs *vs* IAns) |
| Uchida *et al*[41] | Observational | 25 | 25 | DFPP or PE/SPx or RIT | 4.5-yr graft survival: 100% |
| Ashimine *et al*[42] | Observational, comparative | 320 | 92 | DFPP/SPx or RIT or none | 5-yr graft survival: 87% *vs* 97.7% (ABOi *vs* ABOc) |

ABOi: ABO incompatible; SPx: Splenectomy; PE: Plasma exchange; DFPP: Double-filtration plasmapheresis; IAs: Antigen-specific immunoadsorption; ABOc: ABO compatible; CYA: Cyclosporine; AZ: Azathioprine; MZ: Mizoribine; TAC: Tacrolimus; MMF: Mycophenolate mofetil; NA: Not available; RIT: Rituximab; IVIG: Intravenous immunoglobulin; AMMR: Acute antibody-mediated rejection; IAns: Non-antigen-specific immunoadsorption.

**Table 3 Current protocols for ABO incompatible kidney transplantation**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Country, year** | **Rituximab dose** | **Pretranslant IS** | **Antibody depletion** | **IVIG** | **Target titer at the time of transplantation** | **Induction IS** | **Maintenance IS** | **Posttransplant Antibody depletion** |
| **Adult recipients** |  |  |  |  |  |  |  |  |  |
| **Rituximab protocol** |  |  |  |  |  |  |  |  |  |
| Saito *et al*[53] | Japan, 2006 | 375 mg/m2 (twice) at -14 and -1 d | MMF/ MP at -1 Mo | DFPP or PE | - | < 1:16 | BSA (20mg at 0 and 4 d) | CYA/MMF/MP | - |
| Tyden *et al*[54] | Sweden, 2006 | 375 mg/m2 (once) at -1 Mo | TAC/ MMF/ Pred at -13 d | IAs | 0.5g/kg after last IAs | <1:8 | - | TAC/MMF/Pred | IAs, 3 times |
| Chikaraishi[55] | Japan, 2008 | 100 mg/m2 (twice) at -8 and -1 d | MMF/ MP at -14 d, TAC at -3 d | DFPP and PE | - | <1:8 | BSA (20mg at 0 and 4 d) | TAC/ MMF/ MP | - |
| Galliford *et al*[30] | United States, 2008 | 1000 mg (twice) at first day of PE and at the operative day | TAC/MMF at -14 d | PE | 0.1g/kg after each PE | <1:4 | DAC (2 mg/kg at 0 and 14 d) | TAC/MMF/Pred | PE at 1 and 3 d |
| Genberg *et al*[31] | Sweden, 2008 | 375 mg/m2 (once) at -1 Mo | TAC/MMF/Pred at -10 d | IAs | 0.5g/kg at -1day | <1:8 | - | TAC/MMF/Pred | IAs, 3 times |
| Oettl *et al*[32] | Switzerland, 2009 | 375 mg/m2 (once) at -1 Mo | TAC/MMF /Pred at -14 d | IAs | 0.5g/kg after last IAs | < 1:8 | BSA (20mg at 0 and 4 d) | TAC/MMF/Pred | IAs or PE (not routinely) |
| Sivakumaran *et al*[78] | United States, 2009 | 375 mg/m2 (once) at -3 wk | MMF at -1Mo | PE | 2g/kg after last PE | NA | ALE (1 mg/kg at 0 and 14 d) | TAC/ MMF/ Pred | - |
| Wilpert *et al*[34] | Germany, 2010 | 375mg/m2 (once) at -1 Mo | TAC/ MMF or MPS/ Pred at -7 d | IAs | 0.5g/kg at -1 to -5 d | <1:4 | BSA (20mg at 0 and 4 d) | TAC/ MMF/ Pred | IAs (not routinely) |
| Fuchinoue *et al*[36] | Japan, 2011 | 100-1000mg, 1-3 times | CYA or TAC/ MMF at -2 d | DFPP or PE | - | < 1:16 | BSA (20mg at 0 and 4 d) | CYA or TAC/ MMF/ steroid | - |
| Habicht *et al*[37] | Germany, 2011 | 375mg/m2 (once) at -1 Mo | TAC/ MMF/ Pred at -1 Mo | IAs | 30g at -1to -2 d | <1:8 | - | TAC/ MMF/ MP | IAs (not routinely) |
| Lipshutz *et al*[38] | United States, 2011 | 375mg/m2 (once) at -1 Mo | TAC/ MMF at the first day of PE | PE | 10g after each PE | <1:8 | ATG (1.5mg/kg for 4 d) | TAC/ MMF/ Pred | PE (not routinely) |
| Shirakawa *et al*[39] | Japan, 2011 | 500 or 200mg/m2 (once), at -5 to -7 d | TAC/ MMF/ MP at -7 d | DFPP | - | <1:32 | BSA (20mg at 0 and 4 d) | TAC/ MMF/ MP | - |
| Morath *et al*[40] | Germany, 2012 | 375mg/m2 (once) at -1 Mo | TAC/ MMF/ MP at the first day of IAs | IAs | 0.5g/kg after last IAs | <1:16 | BSA (20mg at 0 and 4 d) | TAC/ MMF/ MP | IAs or PE (not routinely) |
| Uchida *et al*[41] | Japan, 2012 | 150mg/m2 (twice) at -14 and 0 d | MMF/ MP at -1 Mo, CYA or TAC at -3 d | DFPP or PE | - | <1:16 | BSA (20mg at 0 and 4 d) | CYA or TAC/ MMF/ MP | - |
| **Rituximab-free protocol** |  |  |  |  |  |  |  |  |  |
| Montgomery *et al*[43] | United States, 2009 | - | TAC/ MMF at the first day of PE | PE | 0.1g/kg after each PE | <1:16 | DAC (2mg/kg initial dose, 1 mg/kg every 2 wk for total 5 doses) | TAC/ MMF/ Pred | PE, at least twice (with IVIG 0.1g/kg) |
| Flint *et al*[35] | Australia, 2011 | - | MMF at -10 to -14 d | PE | 0.1g/kg after each PE | < 1:8 | BSA (20mg at 0 and 4 d) | TAC/ MMF/ Pred | PE (not routinely) |
| Ashimine *et al*[42] | Japan, 2013 | - | MMF at -14 d | DFPP | - | <1:8 | BSA (20mg at 0 and 4 d) | CYA or TAC/ MMF/ Pred | - |
|  |  |  |  |  |  |  |  |  |  |
| **Pediatric recipients** |  |  |  |  |  |  |  |  |  |
| Genberg *et al*[31] | Sweden, 2008 | 375mg/m2 (once) at -1 Mo | TAC/ MMF/ Pred at -10 d | IAs | 0.5g/kg at -1day | <1:8 | - | TAC/ MMF/ Pred | IAs, 3 times |
| Tyden *et al* | Sweden, 2011 [1] | 375mg/m2 (once) at -1 Mo | TAC/ MMF/ Pred at -13 d | IAs | 0.5g/kg after last IAs | <1:8 | - | TAC/ MMF/ Pred | IAs, 3 times |
|  | | | | | | | | | |

IS: Immunosuppression; IVIG: Intravenous immunoglobulin; MMF: Mycophenolate mofetil; MP: Methylprednisolone; DFPP: Double-filtration plasmapheresis; PE: Plasma exchange; BAS: Basiliximab; CYA: Cyclosporine; TAC: Tacrolimus; Pred: Prednisolone; IAs: Antigen-specific immunoadsorption; DAC: Daclizumab; NA: Not available; ALE: Alemtuzamab; MPS: Mycophenolate sodium; ATG: Antithymocyte globlin.

**Table 4 Pro and cons for ABO incompatible kidney transplantation**

|  |
| --- |
| Pro ABOi-KT |
| Reducing waiting list and time |
| Expanding living donor pool |
| Improvement of patient's prognosis |
| Excellent graft survival (comparable with ABOc-KT) |
|  |
| Contra ABOi-KT |
| Comparative high immunological risk |
| Higher incidence of acute AMR |
| Intensified immunosuppression |
| Antibody depletion therapy |
| Increasing expenditure |
| Higher incidence of viral infection |
|  |

ABOi-KT: ABO incompatible kidney transplantation; ABOc-KT: ABO compatible kidney transplantation; AMR: antibody-mediated rejection.